Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Lonza
 More »

  • GEN | Biolinks
    ... Lixte Biotechnology Holdings, Inc Lonestar Heart, Inc Lonza (LCM) Louisana Economic Development Luitpold Pharmaceuticals, Inc. Lumigen -- a Wholly Owned Subsidiary pof Beckamn ...
  • Biosimilars: 10 Drugs to Watch
    ... and Lonza: End planned 544-patient, Phase III clinical trial of TLO11, saying they wanted input from regulators on designing the trial program (October 2012). On April 5, Lonza ...
    4-22-2013
  • Medicine: Getting Personal
    ... Kim Warren, head of development services for cell therapy at Lonza, commented on one of the challenges in moving the production of adherent cells to bioreactors and the use of ...
    3-15-2013
  • Biosimilars: Not So Far So Fast
    However, the company said, given the changes in the regulatory and competitive environment, "Teva (through its joint venture with Lonza) is evaluating the path forward for ...
    3-15-2013
  • Lonza and Hyglos Reach Agreement Settling Patent Dispute
    Lonza Walkersville and Hyglos signed an agreement that allows Hyglos to use recombinant ... The agreement also includes the dismissal of the lawsuit Lonza previously filed against ...
    3-14-2013
  • Electrophoretic Power Supply
    Lonza Muenchensteinerstrasse 38 SWITZERLAND CH-4002 Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and ...
    2-1-2013
  • Single-Use Systems Entice Multiple Users
    ... with standardization, which is why Lonza continues to fine tune its GS Gene ... GS Gene Expression is designed to work with the GS-CHO cell line, for which Lonza claims ...
    1-15-2013
  • Where Downstream Operations Are Headed
    II dosing range studies. "However, it is a very competitive marketplace, and Teva and Lonza have already halted their rituximab biosimilar development, so looking at areas such as ...
    1-1-2013
  • Sartorius Stedim Biotech Inks Cell Culture Deal with Lonza
    Sartorius Stedim Biotech (SSB) signed a cooperation agreement with Lonza covering cell ... therapeutics and vaccines, while Lonza will continue to carry out development, ...
    12-19-2012
  • Inventive Approaches Redefine Downstream Ops
    Lonza Biologics, for example, has developed a platform process for monoclonal antibody ... To alleviate a downstream bottleneck, the Lonza team adopted less compressible matrices ...
    12-1-2012
  • Optimizing Cell Lines Improves Production-Really!
    That was one of the main messages delivered at CHI's "Bioprocessing Summit", in the late summer. Jesús Zurdo, Ph.D., head of innovation for biopharma development at Lonza ...
    11-15-2012
  • Lonza to Manufacture OncoMed's Anticancer Antibody Pipeline
    Lonza and OncoMed Pharmaceuticals signed a process development and manufacturing ... Under terms of the contract Lonza will carry out process development and production of ...
    10-23-2012
  • Cellectis Wins Up to $9.5M NIH Stem Cell Contract
    Cellectis' deal with NIH follows just a week after Lonza announced winning a roughly $9.5 million contract from the NIH Center for Regenerative Medicine for the cGMP manufacture of ...
    10-17-2012
  • EC Pledges $7.8M for Trials of HLH Therapeutic Antibody
    HLH, will be headed by NovImmune and include the Meyer University Children Hospital (Florence, Italy), the Pediatric Hospital Bambino Gesú (Rome, Italy), and Lonza Biologics. ...
    10-15-2012
  • Lonza Wins U.S. Gov't iPSC Manufacturing Contract
    Lonza won a roughly $9.5 million National Institutes of Health Center for Regenerative ... In August Lonza negotiated a global license to the iPSC stem cell technologies invented by ...
    10-10-2012

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll